Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial

Abstract Background Glucagon-like peptide 1 analogs are expected to exert a cardio-protective action due to their effective glucose-lowering action and favorable potency on multifactorial metabolic pathways. However, the safety and tolerability of liraglutide treatment after a recent acute coronary...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cardiology 2017-03, Vol.69 (3), p.511-517
Hauptverfasser:	Kajiwara, Masataka, MD, Tanaka, Atsushi, MD, PhD, Kawasaki, Tomohiro, MD, Nakao, Koichi, MD, PhD, FJCC, Sakamoto, Tomohiro, MD, PhD, FJCC, Toyoda, Shigeru, MD, PhD, FJCC, Inoue, Teruo, MD, PhD, FJCC, Koga, Nobuhiko, MD, Node, Koichi, MD, PhD, FJCC
Format:	Artikel
Sprache:	eng
Schlagworte:	Blood Glucose - metabolism Body Weight - drug effects Cardiac function Cardiac ultrasonography Cardiovascular Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Drug Administration Schedule Echocardiography Female Glucagon-like peptide 1 analog Humans Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Lipids - blood Liraglutide Liraglutide - adverse effects Liraglutide - therapeutic use Male Middle Aged Myocardial Infarction - complications Myocardial Infarction - diagnostic imaging Myocardial Infarction - surgery Percutaneous Coronary Intervention Pilot Projects Prospective Studies Type 2 diabetes mellitus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!